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Background. Tubal patency testing is an essential part of female subfertility evaluation. Traditionally, hysterosalpingography (HSG)
was the first step to evaluate tubal patency. However, during the past decade Hysterosalpingo-Contrast Sonography (HyCoSy) was
introduced in order to avoid radiation exposure andHysterosalpingo-Foam Sonography (HyFoSy) has been developed as a safe and
less painful alternative.Objectives and Rationale.The aim of this narrative review is to provide an overview of the currently available
HyFoSy literature and related clinical aspects. Search Methods. A literature search was conducted using PubMed and Embase from
the introduction of HyFoSy to March 2019. Unfortunately, a meta-analysis was not possible due to a too small number of studies,
beingmutually incomparable for the various subjects of clinical aspects, even for the reliability as a test for tubal patency.Outcomes.
Nine small studies concluded that the accuracy and effectiveness as a test for tubal patency of 2D- and 3D-HyFoSy are comparable
or even better than HSG or HyCoSy. With or without using Doppler techniques, 3D-HyFoSy does not seem to offer benefits above
real-time 2D-HyFoSy. Five studies reported on pain and discomfort during HyFoSy, concluding that HyFoSy is a well-tolerated, less
painful procedure compared to HSG, without a need for the use of analgesics. There are suggestions about an increased pregnancy
rate in the first three cycles after the procedure but in no studies pregnancy outcome after HyFoSy was compared with other or
no intervention.Wider Implications. HyFoSy is a promising and safe alternative for HSG with regard to accuracy and effectiveness.
HyFoSy lacks radiation and iodine exposure and is a well-tolerated and less painful procedure than HSG, without the need for
analgesics. However more research is needed to make clear statements regarding a therapeutic effect of HyFoSy.
1. Introduction
Tubal patency testing is an essential part of female subfertility
evaluation [1]. Tubal abnormalities are seen in 30-40% of
female subfertility patients [2]. Laparoscopy (LSC) with
chromopertubation is considered to be the gold standard
diagnostic procedure [3]. LSC is an invasive test, with a risk of
intra-abdominal bleeding, visceral damage, and risks related
to general anaesthesia. Traditionally, hysterosalpingography
(HSG) is a less invasive first-step alternative, which has been
used for decades. Considering the disadvantages of HSG
such as radiation exposure, discomfort, or even abdominal
pain, Hysterosalpingo-Contrast Sonography (HyCoSy) was
introduced as an alternative [4, 5] using either contrast
media or saline. The accuracy of HyCoSy is comparable to
that of HSG and LSC [6, 7] being reference standards for
tubal patency testing. An advantage of ultrasound is that,
in addition to tubal patency, information is also obtained
about pelvic anatomy including uterus and ovaries. Avoiding
pregnancy in the treatment cycle is extremely important in
HSG procedures.
There are indications that the accuracy of HyCoSy may
improve by using 3D imaging techniques [8, 9]. Recently it
was claimed in a LSC controlled study [10] that not only tubal
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patency but also peritubal adhesion could be assessed with
HyCoSy by observing a lower “spray score” at the fimbrial
end. In a large systematic review with meta-analysis [11] no
benefit was found of commercially available contrast media
over saline and Doppler sonography was associated with a
greater sensitivity and specificity.
However, hyperechogenic contrast media such as Echo-
vist (Schering AG, Berlin) and SonoVue (Bracco, Milan)
are either no longer available or not licensed for tubal patency
testing. Hysterosalpingo-Foam Sonography (HyFoSy) was
developed as an alternative for contrast HyCoSy and was
introduced in 2010 [12] as a first-line office tubal patency
test. Foam is used in the HyFoSy technique to visualize
the Fallopian tubes and is created by rigorously mixing 5ml
ExEm-gel (containing hydroxyethyl cellulose and glycerol,
IQMedical Ventures BV, Rotterdam,TheNetherlands) with 5
ml purified ExEm-water. The ExEm-foam, with a viscosity
of 270 cP and containing 94.12 % water, is sufficiently fluid
to pass the Fallopian tubes and in the meantime sufficiently
stable to show echogenicity for at least five minutes, which
is an advantage over saline. In a review on safety aspects
and side effects of ExEm-gel [13] it was considered to be
appropriate and safe for tubal patency testing. This was
confirmed in a recently published retrospective study [14]
among 155 women undergoing HyFoSy, reporting no side
effects at the follow-up appointment.
This review on tubal patency testing is intended as an
update of the literature focusing on clinical aspects of HyFoSy
in subfertility workup, like diagnostic accuracy and side
effects, 3D andDoppler flow techniques, discomfort and pain,
intravasation, pelvic inflammatory disease prevention, and
enhancing the chance of pregnancy.
2. Methods
A literature searchwas conducted using PubMed and Embase
from the introduction of HyFoSy to 12 March 2019. We
searched with terms related to the index test HyFoSy and did
not use any filter to maximize the sensitivity of the search.
Studies on the use of HyFoSy to confirm occlusion after tubal
sterilization were excluded.
Unfortunately, a meta-analysis was not possible due to a
too small number of studies, beingmutually incomparable for
the various subjects of clinical aspects, even for the reliability
as a test for tubal patency. We therefore decided to provide
a description of published findings and facts as an update of
the literature on this subject. The results are summarized in
a table containing references per subject, type of the study,
study design, and main results (Table 1).
3. Diagnostic Accuracy and Side Effects
The first report on efficacy of HyFoSy [15] was a prospective
observational cohort study in 73 subfertile women undergo-
ing a HyFoSy. A successful procedure was performed in 67
(92%) of these 73 women. In 57 women (78%) tubal patency
was observed and no further examination was needed. In
5 women (7%) tubal occlusion was confirmed by HSG and
in another 5 women (7%) there was a discrepancy between
HSG and HyFoSy findings. Five patients experienced vaso-
vagal discomfort during or after the procedure that resolved
spontaneously in time. No serious adverse effects occurred.
In the second observational cohort study [16], comparing the
results of 20 HyFoSy procedures with LSC, there was a 100%
agreement between HyFoSy and LSC.
In a randomized controlled selective crossover trial
(n=40) comparing HyFoSy with saline HyCoSy [17], the
proportion of Fallopian tubes that were classified as patent
was higher in the HyFoSy group compared to saline HyCoSy
(70,0% versus 40,0%, p=0.01). On crossover testing HyFoSy
also performed better than saline HyCoSy. No major post-
procedural complications were observed.
In a randomized controlled study in 37 infertile women
scheduled for LSC [18], the results of HyFoSy and saline
HyCoSy were compared with LSC findings. Tubal patency
was in the HyFoSy group concordant with LSC in 94,4%
of cases (sensitivity 87,5% and specificity 100%) compared
to 57,8% in the saline HyCoSy group (sensitivity 50% and
specificity 66,6%). In a prospective observational study [19] in
132 women HyFoSy and HyFoSy with High Definition Flow
(HDF) Doppler technique was compared to saline HyCoSy
and LSC as gold standard. Saline HyCoSy and HyFoSy were
in comparison to LSC both significantly less accurate (84.2%;
p<0.01, respectively, 92.1%; p<0.01) whereas HyFoSy with
HDF Doppler did not significantly differ from LSC (95,8%;
p<0.07). Although HyFoSy with and without HDF Doppler
technique performed better, the authors conclude that saline
HyCoSy may be used as an initial test because of its high
negative predictive value on tubal occlusion (99.6% versus
99.5%, respectively; 99% for HyFoSy without HDF Doppler
technique).
It is good to realize that it is easier to diagnose tubal
patency than tubal occlusion due to a difficult differentiation
between true and false occlusion caused by, for example, a
mucus plug or a spasm [20]. Actually there is no diagnostic
test for tubal occlusion, only for tubal patency.
4. 3-Dimensional Ultrasound and Doppler
Flow Techniques
HyCoSy with saline (and air) is, in comparison to HyFoSy,
more observer-dependent due to the fact that the hyperechoic
characteristics are usually lost within a short time and the
inability to examine the whole course of the Fallopian tube
in one scanning plane [7]. In attempts to overcome these
problems 3-dimensional ultrasound (3D-US) and Doppler
techniques [21] were introduced. As the hyperechoic char-
acteristics of HyFoSy are much more stable, there is more
time for routine 2D ultrasound. It is therefore questionable
whether these techniques are of additional value for HyFoSy.
In a prospective observational study [22] in 132 subfertile
women, all women underwent HyFoSy with new automated
3D coded contrast imaging (CCI) software (GE Healthcare)
with two foam injections followed by 2D real-time HyFoSy.
Because the ExEm-foam was too viscous to pass through the
5 French HyFoSy balloon catheter, the investigators prepared
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Figure 1: An example of 2DHyFoSy.The clear white line is sufficient
evidence for an open Fallopian tube.
a different and unusual off-label ExEm-gel dilution. The
concordance rate between the first and second 3D volume
reconstruction and the final 2D real-time evaluation was
84.8% and 97.0%, respectively. Vasovagal reactions were
observed in two patients and no other adverse effects were
noted.
Riganelli et al. [23] described in a pilot study the
results of a randomized controlled trial in 50 women who
were previously subjected to LSC and randomly assigned
to 2D-HyFoSy or 3D-HyFoSy. The 2D-HyFoSy was in 81%
of the cases concordant with the LSC, with a sensitivity
of 80% and a specificity of 92%. The 3D-HyFoSy was in
88% concordant with LSC, with a sensitivity of 98% and
a specificity of 91.4%. Statistical analysis of this difference
is lacking in this study. The 3D-HyFoSy procedures were
found to be less painful and faster (P<0.001). In the dis-
cussion the authors state that 3D-HyFoSy is less operator-
dependent and more reproducible and it allows postproce-
dural reconstruction of images. They conclude that, in low
risk patients, if the tubes appear obstructed in 2D-HyFoSy,
3D-HyFoSy seems advisable before submitting patients to
LSC.
Ludwin et al. [24] concluded from their retrospec-
tive study in 50 women that the interobserver reliability
and agreement on the diagnosis of tubal patency using
stored videos improved when HyFoSy combined with power
Doppler technique was used in comparison to 2D-HyCoSy.
The relatively small number of patients in this retrospective
study and the lack of real-time 2D information are limita-
tions.
With or without using Doppler techniques, 3D-HyFoSy
does not seem to offer benefits above real-time 2D-HyFoSy
performed by an ultrasonographer who is familiar with pelvic
anatomy (Figure 1). The clear white line indicating foam
passage through the proximal part of the tube is sufficient evi-
dence for the absence of a distal occlusion as is known from
studies using hysteroscopy and air bubbles [25]. Anyway,
from the nine clinical studies [15–24], it can be concluded
that HyFoSy appears to be accurate and well-tolerated first-
line diagnostic procedure and the 3D-HyFoSy technique is
helpful for a less experienced operator. Furthermore, 3D
scanning offers standardization of pelvic scanning and its use
is superb for educational purposes. Recently a novel concept
named Fertilityscan© was described [26] using 3D-HyFoSy
as a women-friendly and cheap assessment for both anatomy
and function of the uterus, ovaries, and tubes.
5. Discomfort and Pain
Intrauterine application of contrast media may cause discom-
fort and pain. This may be due to the dilatation of the cervix,
application of a catheter, filling of the cavity under pressure,
the composition of the contrast medium, or a combination
of factors. In an observational study [27] on 483 patients
undergoing saline HyCoSy via a paediatric balloon catheter
no pain was observed in 30.0%,mild pain in 49.7%,moderate
pain in 13.5%, and severe pain in 6.8% and vasovagal reactions
were seen in 4.9%.
In general, a gynaecological examination is for the major-
ity of patients embarrassing and stressful, enhanced by fear
or pain [28]. It is important to explain the procedure before
starting the examination, to insert the speculum slowly, and,
most importantly, to inject the medium very slowly to avoid
high intrauterine pressure.
Five studies have been published regarding pain expe-
rience during HyFoSy. The first [29] was a randomized
controlled trial including 40 women, comparing visual ana-
logue scale (VAS) pain score during tubal patency testing
using HyFoSy and serial HSG. For HyFoSy, a small cervical
balloonless catheter was placed. For HSG, a hysterophore
with one tenaculum on the anterior cervical lip was used.
All media were injected in the uterine cavity with the use
of an electrical pump with a standardized flow and pressure.
This trial showed a lower VAS score in the HyFoSy group
compared to the HSG group (median VAS score 1.7 cm;
interquartile range (IQR) 4.2 versusmedianVAS score 3.7 cm;
IQR 3.0; P<0.01).
In a cross-sectional study [30] on 216 patients the median
VAS score for pain during transvaginal ultrasound (TVU)
and subsequent HyFoSy was 1.5 cm (95% CI, 1.2-1.7) and
3.6 cm (95% CI, 3.0-4.0), respectively. To instil the foam, a
balloon catheter was placed. One in three women reported
the same level of discomfort or pain during TVU as for
HyFoSy; 48% of the women reported the HyFoSy to be
neutral/unpleasant, but not painful. There was an inverse
association between both patient’s age and parity and expe-
rienced pain [30].
In a randomized controlled trial [31] including 40women,
HyFoSy was performed using two different balloon catheters,
uVue HSG catheter or a paediatric Foley’s catheter. It was
concluded that a paediatric Foley catheter was easier to insert
and the HyFoSy was less painful compared to HyFoSy using
uVue HSG catheter.
One study has been published [32] concerning the use of
analgesics during 2D/3D Doppler HyFoSy. In a prospective
observational study 300 women were subjected to uterine
cavity and tubal patency ultrasound assessment and asked to
report VAS pain scores. From October 2012 until March 2013
the procedure was performed without any analgesics in 125
women. From March until the end of the study 175 women
received approximately 1 hour before the procedure a tablet
containing paracetamol 500mg and codeine phosphate 30mg.
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During 2D/3D-Doppler-HyFoSy, the median VAS pain score
was significantly higher for women not using analgesics
(median VAS score 2.0 cm; IQR 1.0-3.0 versus a median VAS
score 3.0 cm; IQR 1.3-4.0; p= 0.002).
There are no other studies concerning pain and the
placement of the catheter, filling of the uterus, and local or
systemic anaesthesia during HyFoSy.We therefore will report
on these aspects in relation to gel instillation sonography
(GIS), saline infusing sonography (SIS), HSG, and HyCoSy.
5.1. The Use of Catheter. It has been suggested [33] that SIS
performed with an infant feeding tube without a balloon
is associated with very low pain levels in comparison to
catheters with a balloon (median pain score 10, on a scale of
0-100). That is consistent with the theory that most sensory
receptors are located in the area of the cervical internal
ostium. On the other hand, Dessole et al. [34] compared
six different catheters, used in 568 sonohysterograms. The
diameter of the catheters varied fromCharrier 5 toCharrier 8,
five had a balloon at the tip with a capacity of 3-5mL, and one
was equipped with a movable stopper, which is fixed to the
external os of the uterus. The authors did not find significant
differences with regard to reliability, the physician’s ease of
use, the insertion time, the volume of contrast medium, and
pain.
5.2. Type and Temperature of Contrast. The influence of the
contrast medium (Echovist versus saline) and the tempera-
ture (25∘C versus 37∘C) was investigated in a prospective ran-
domizedHyCoSy study [35] including 138 patients. Echovist
induced significantly less pain in comparison to saline at the
same temperature (p=0.002 and p=0.001). Between the two
groups there was also a significant difference in pain during
the introduction of the same contrast at different temperature
(p<0.001). The most tolerable one for the patient is body
temperature. This applies for both contrast media. These
results may indicate that Echovist is more “patient-friendly”
than saline. In another study [36] on pain experience during
SIS (n=99) it was observed that postmenopausal women
experienced pain more often than premenopausal women
(71% versus 32%; p<0.002). Also the character of the pain
in relation to saline was different: postmenopausal women
more often felt a sharp pain (42%), whereas premenopausal
womenmore often felt gnawing and/or cramping pain (21%).
This may be related to the thin atrophic endometrium
in postmenopausal women. Furthermore, in a randomized
study on 200 HSG procedures [37] it was observed that
warming the contrast to body temperature is associated with
less pain and fewer vasovagal episodes.
5.3. Analgesics. In a randomized double-blinded placebo-
controlled trial [38] 127 women received 3 mL 2% lidocaine
solution or 0.9% normal saline before undergoing a HSG.
As there were no differences with respect to pain scores
between both groups, intrauterine lidocaine did not appear
to be effective. In a smaller study of 106 women [39], a
beneficial effect of intrauterine lidocaine was only seen in
parous women undergoing SIS. In a study on 132 patients
[40] undergoing GIS with and without lidocaine containing
gel prior to a hysteroscopy no differences were seen either.
From another randomized double-blind placebo-controlled
trial [33] on 120 patients undergoing SIS it could be concluded
that topical or local intrauterine application of lidocaine was
not effective in reducing pain.
From a systematic review on pain relief in HSG [41]
it was concluded that topical analgesics applied before the
procedure may be effective, although the available evidence
was of low quality. Also, intravenous opioids may be effective
though this must be weighed against their side effects. In
other systematic reviews and meta-analysis [42, 43] it was
concluded that there is no evidence of significant benefit in
using any analgesia before HyCoSy or HSG compared to
placebo.
Mechanical distension of the uterine walls may cause
a release of prostaglandins, resulting in uterine cramps.
However in a large randomized double-blind clinical trial
[44] (n=816) there was no difference in pain scores between
a group receiving an antispasmodic drug (hyoscine-N-
butylbromide) during HyCoSy or a placebo. In another study
[45] administration of 1000 mg paracetamol and 600 mg
ibuprofen one hour prior to office hysteroscopy did not
reduce pain scores. Rectal indomethacin, however, reduced
the pain significantly during HSG in a randomized placebo-
controlled trial [46].
With regard to discomfort and pain it can be concluded
from all available literature that HyFoSy is a well-tolerated
procedure, less painful than HSG. There is no role for local
and general analgesia. Prophylactic analgesia is not necessary
and, in case it is nevertheless considered, rectal application of
Indomethacin or codeine tablets seems to be effective.
6. Intravasation
Venous intravasation is a well-known complication of HSG,
occurring in about 6.4% of cases [47]. Rarely cerebral and
pulmonary oil embolism after oil-soluble contrast media
(OSCM), like Lipiodol, has been described in case reports
and after water-soluble contrast mediaWSCM complications
like fever, infection, and pain have been described. In a study
on HyCoSy with SonVue intravasation occurred in 13.04%
of 276 patients [48]. The incidence of intravasation was high
in case of thin endometrium and high pressure and low on
days 5-7 after ending of the menstrual period. Recently a
first case on intravasation during HyFoSy has been published
[49]. As hydroxyethyl cellulose and glycerol are safe, even
in case of intravenous application [13], no clinical signs or
complications occurred.
7. Pelvic Inflammatory Disease Prevention
As described in the first paragraph, no major postprocedural
complications after HyFoSy were observed in nine obser-
vational studies [15–24]. Glycerol, one of the components
of ExEm-gel, is known to have antimicrobial and virucidal
effects [50]. Fever and peritonitis occurred in only 0.95%
of 1.153 patients undergoing sonohysterosalpingography [51].
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From HSG studies [52] it is known that only patients with
an existing hydrosalpinx are at risk of PID and may benefit
from prophylactic antibiotics. Age under 25 years, first sex
at an early age, lower socioeconomic status, and exposure to
chlamydia trachomatis are risk factors for PID [53].
Routine antibiotic prophylaxis is not beneficial and is
not recommended in diagnostic hysteroscopy, because of the
very low risk of infection [54–56]. In a Cochrane Review
on antibiotics for transcervical intrauterine procedures [57]
it was concluded that no trials were eligible for inclusion
and it is therefore not possible to draw any conclusion.
In a large systematic review on antibiotic prophylaxis for
gynaecological procedures prior to and during the utilization
of assisted reproductive technologies [58] it is also concluded
that routine antibiotic prophylaxis is generally not recom-
mended for these procedures. However, patients at risk of
pelvic infections should be screened and treated prior to
procedures such asHSG, SIS, HyCoSy, HyFoSy, hysteroscopy,
embryo transfer, and chromopertubation.
8. Enhancing the Chance of Pregnancy?
Up until now, only observational studies are available con-
cerning the chance of subsequent pregnancy after HyFoSy.
A retrospective study [59] reported on a 55% pregnancy
rate in 359 women after HyFoSy during a variable follow-
up period of 3 to 42 months. In this study the number of
pregnancies was the highest in the cycle of the HyFoSy and
the first two cycles after the procedure. In a retrospective
cohort study [14], among 111 subfertile women, 48 (43.2%)
women conceived within 6 months after HyFoSy, of whom
24 women conceived naturally. Emanuel et al. [15] reported a
natural conception rate of 19.2% with a median of 3 months
after the HyFoSy procedure. In a retrospective observational
study [60] regarding 294 subfertile women who underwent
HyFoSy, 157 women provided information by phone on their
fertility after 12 months. The authors observed a cumula-
tive spontaneous pregnancy rate of 10.2% within 1 month
after HyFoSy, 29.9% within 6 months, and 34.4% within 12
months.
More is known about the fertility enhancing effect of
tubal flushing at HSG [61]. Tubal flushing with (OSCM) is
increasing the odds of pregnancy and live birth in comparison
to no intervention or WSCM [62]. It is uncertain whether
this is a “tubal flushing” phenomenon, an effect on the
intraperitoneal environment, or an implantation enhancing
effect on the endometrium. Flushing with an OSCMhas been
proven to be effective in endometriosis-related infertility
[63]. In a recent Cochrane Review [64] the efficacy of tubal
flushing with OSCMorWSCMwas evaluated. In comparison
to no intervention the OSCM group had a higher rate of life
birth (OR 3.09, 95% CI 1,39–6.91) compared to the WSCM
group (OR 1.13, 95% CI 0.67–1.91). Recently a multicentre
RCT on 1119 patients [65] showed significantly more ongoing
pregnancies in the first 6 months following HSG with OSCM
as compared to HSG with WSCM (39% versus 29%, RR
1.38; 95% CI, 1.17 to 1.64; P<0.001). The increased number
of pregnancies in this study was found to be based on pain
experienced during the procedure [66]. The use of OSCM
in HSG procedures is associated with the occurrence of
peritoneal granulomata [67], neonatal hypothyroidism [68],
and immunological effects [69].
The clinical impression of enhanced pregnancy rates after
HyCoSy with WSCM (Echovist) could not be confirmed
in a prospective randomized study [70] (n=334). In an
observational study on 180 patients after saline HyCoSy [71]
a possible beneficial effect of HyCoSy was observed directly
after the procedure. The pregnancy rate was significantly
higher in the first 30 days after HyCoSy (45%) compared
to other months of observation after HyCoSy (p<0.0005).
One has to keep in mind however that this is comparable
to a 42% natural conception rate observed [72] in the first
cycle of the normal population. In a retrospective study
[73] on 559 patients treated with intrauterine insemination
(IUI) it was observed that the cumulative pregnancy rates
(mean 2,3 cycles) after LSC, saline HyCoSy, and HSG were
30%, 41%, and 38%, respectively. In a recent post hoc
analysis of a prospective multicentre cohort study [74] among
4556 couples with unexplained infertility HSG increased
the ongoing pregnancy rate compared to no HSG (adjusted
hazard ratio 1.40, 95% CI 1.16-1.70) regardless of WSCM
or OSCM was used. Furthermore, in a large study on 1008
infertile patients patency of both Fallopian tubes and the
absence of injective resistance turned out to be independent
factors associated with the ability to conceive after HyCoSy
[75].This is consistent with the one-half reduction of clinical
pregnancies in a large study on the effect of unilateral tubal
abnormalities on the results of intrauterine inseminations
[76].
In a prospective randomized controlled trial on intrauter-
ine saline infusion as a form of pregnancy enhancing
endometrial injury during IVF cycles in 63 patients with
recurrent implantation failure [77] a possible negative effect
of saline on reproductive outcomes was observed. In this
study a clinical pregnancy occurred in 1 out of the 20
women undergoing intrauterine saline infusion on days 3-
5 in the stimulation phase as opposed to 9 out of 43
women without an infusion (p<0.05). In a randomized study
[78] comparing uterine bathing with OSCM prior to IVF
with IVF alone, no evidence was found of any beneficial
effect.
ExEm-foam is safe and even passed the mouse-embryo-
test [13]. Although in observational studies we could not find
any negative effect on fertility after the HyFoSy procedure, we
have to conclude that no studies on postprocedure pregnancy
rates are available comparing HyFoSy with other or no
intervention.
9. Conclusion and Discussion
Although most of the studies presented in this review are
small with an observational design, it can be concluded
that HyFoSy is a promising alternative for HSG with regard
to accuracy and effectiveness. HyFoSy lacks radiation and
iodine exposure, which is a benefit in comparison to HSG.
With or without using Doppler techniques, 3D-HyFoSy
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does not seem to offer benefits above real-time 2D-HyFoSy.
However, 3D scanning offers standardization of pelvic scan-
ning and may be performed by a less experienced opera-
tor. HyFoSy is a well-tolerated and less painful procedure
than HSG without a need for the use of analgesics. No
serious or severe complications have been reported after
more than 350.000 procedures. Routine antibiotic prophy-
laxis is generally not recommended; however patients at
risk at pelvic infections should be screened and treated
accordingly prior to the HyFoSy procedure. Moreover, there
appears to be no detrimental effect of HyFoSy on fertility
and there might even be a beneficial effect in the first
three menstrual cycles after the procedure on enhancing
pregnancies.
10. Future Perspectives
As HyFoSy is still a relatively new tubal patency test, only
observational data are available. Therefore, robust random-
ized controlled trials are needed to draw firm conclusion
on the degree of accuracy and effectiveness of HyFoSy and
the fertility enhancing effect. As ExEm-foam is not yet
FDA-approved, large trials and clinical use of HyFoSy in
the US are lacking. In the Netherlands a large randomized
controlled study, the so-called FOAM trial, comparing the
effectiveness and costs of HyFoSy with HSG, is currently
ongoing [79]. In this study subfertile patients (N=1163), who
are scheduled for tubal patency testing during their fertility
workup, undergo both HSG and HyFoSy in a random order.
If the results of both tubal tests are discordant, women will be
randomly allocated to either amanagement strategy based on
HyFoSy or amanagement strategy based onHSG, implicating
either a LSC or a strategy that assumes tubal patency. The
primary outcome of this trial is an ongoing pregnancy
leading to live birth within 12 months after randomization.
Recruitment for this trial is expected to be completed in the
fall of 2018. Therefore, the results will be available around
2020.
With regard to the fertility enhancing effect randomized
controlled trials comparing HyFoSy with other or no inter-
vention are urgently needed.
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